Smart Capital Traders
  • Politics
  • Investing
  • Latest News
  • Stocks

Smart Capital Traders

  • Politics
  • Investing
  • Latest News
  • Stocks
Politics

Dr. Oz becomes next head of Medicare and Medicaid Services following approval from full Senate

by admin April 4, 2025
April 4, 2025
Dr. Oz becomes next head of Medicare and Medicaid Services following approval from full Senate

Dr. Mehmet Oz will serve as the next administrator of the Centers for Medicare and Medicaid Services after the full Senate voted along party lines to confirm his nomination on Thursday. 

The former daytime TV doctor turned politician will be in charge of nearly $1.5 trillion in federal healthcare spending. His duties will entail overseeing Medicare, Medicaid and the Children’s Health Insurance Program (CHIP), including directing decisions related to how the government covers procedures, hospital stays and medication, as well as the reimbursement rates at which healthcare providers get paid for their services.   

Medicare is a federal healthcare program for seniors aged 65 and up, and currently provides coverage to about 65 million Americans, according to the Center for Medicare Advocacy. Medicaid, a public health assistance program for people with low incomes, covers roughly 72 million Americans, according to Medicaid.gov. Meanwhile, CHIP, which provides free or low-cost health coverage for eligible low-income children and family members, assists around 7.2 million individuals. 

A graduate of Harvard University, Oz received medical and business degrees from the University of Pennsylvania. He is a former heart surgeon who saw his fame rise through his appearances on daytime television, including ‘The Oprah Winfrey Show,’ and 13 seasons of ‘The Dr. Oz Show.’

Oz later transitioned into politics, launching an unsuccessful bid for Pennsylvania’s open Senate seat in 2022. He lost to John Fetterman, then the state’s lieutenant governor.

‘Dr. Oz has a strong desire to modernize CMS and encourage healthy lifestyles for all Americans, including by focusing on the underlying causes of chronic disease and implementing innovative technologies,’ Senate Finance Committee Chairman Sen. Mike Crapo, R-Idaho, said Thursday.

Crapo, who led Oz’s nomination process at the committee level, commended Oz for his ‘diligence and accessibility’ throughout the process, including his willingness to answer ‘hundreds’ of questions for the record.

Those questions came from both Republicans and Democrats. They included asking about Oz’s stance on abortion, transgender medical treatments, Medicare privatization, prescription drug pricing and more. Potential financial conflicts of interest were also a concern among Democratic lawmakers throughout Oz’s confirmation process. Oz has committed to divesting any holdings that may pose an issue. 

Thursday’s confirmation comes as the Trump administration continues to work to finalize the rest of its political appointments, including notably the president’s pick to be the next United Nations ambassador and his pick for director of the Consumer Financial Protection Bureau. 

Per The Washington Post’s ‘political appointee tracker,’ there are currently still 233 nominees being considered by the Senate.

This post appeared first on FOX NEWS

previous post
Waltz’s Signal chat woes snowball as Trump admin defends national security advisor
next post
Bitcoin Holds Up, but Remains Short of Relative Breakout

related articles

Trump offers to release his October MRI results,...

December 1, 2025

Rep Gimenez warns China is ‘greatest threat’ to...

December 15, 2024

North Korea fires cruise missiles as Kim underscores...

December 30, 2025

Schumer ripped for placing blame on Trump, DOGE...

May 20, 2025

US allows Russian oil tanker to reach Cuba...

March 30, 2026

How AI browsers open the door to new...

September 21, 2025

Policy group praises Trump’s 100 global wins since...

December 17, 2025

Trump secures release of American trapped in Saudi...

November 20, 2025

Trump’s Operation Warp Speed sparks GOP call for...

October 21, 2025

National security experts sound alarm over CCP-linked land...

January 9, 2026

    Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Most Popular

    • 1

      Bold Ventures Announces Final Closing of Non-Brokered Private Placement and Insider Subscriptions

      October 19, 2024
    • 2

      Retraction of Forecast Financial Information Plus Announcement on New Metallurgical Testwork Results

      October 15, 2024
    • 3

      Environmental Approval for Boland Infield Studies & Update on Scaled Column ISR Test

      September 19, 2025
    • 4

      Emyria and UWA in Partnership to Commercialise Novel Serotonin-Releasing Agents for Mental Health and Neurology

      October 31, 2024
    • 5

      As North Korea, Iran and China support Russia’s war, is a ‘new axis’ emerging?

      October 25, 2024

    Categories

    • Investing (3,716)
    • Latest News (2,300)
    • Politics (4,595)
    • Stocks (1,368)
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: smartcapitaltraders.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.


    Copyright © 2025 smartcapitaltraders.com | All Rights Reserved